Melanotan II in Melanocortin Receptor Pharmacology: A Research Literature Overview

Melanotan II (MT-II) is a cyclic, truncated analogue of the ACTH(4-10)/alpha-melanocyte-stimulating hormone core sequence, described in the literature as a potent and largely non-selective agonist at melanocortin receptors (MCRs) [3][1]. A historical review of melanocortin peptide therapeutics documents that MT-II and the linear analogue melanotan I were patented and taken into clinical testing, with MT-II examined in human studies related to erectile function and its analogue PT-141 progressing through phase I/II trials [3]. That review is the principal human-oriented source in this set; the remaining primary reports are in vitro or animal work. Structure-activity work has used MT-II as a scaffold for probing receptor subtype selectivity. In an in vitro medicinal-chemistry study, the lactam bridge of MT-II was replaced with xylene-derived thioether linkages using a peptide-on-scaffold cyclisation strategy; the resulting analogues bound human MCRs with affinities spanning low nanomolar to sub-micromolar values, and one compound showed functional selectivity for hMC1R that the parent MT-II did not [2]. Enhanced-sampling molecular dynamics simulations in the same report linked the cyclisation chemistry to conformational behaviour and measured hMC1R affinity [2]. Earlier in vitro characterisation on cloned rat brain MC3 and MC4 receptors compared nine melanocortin ligands and reported that the potency ranking of MC4 receptor agonists, but not of MC3 receptor agonists, matched the potency of the same ligands to induce grooming behaviour in rats after intracerebroventricular administration; MT-II also induced grooming after intravenous administration in that study [7]. Several animal studies have addressed where systemically administered MT-II acts. In rats, intravenous MT-II and iodinated MT-II suppressed food intake, while autoradiography after intravenous (125)I-MT-II detected labelling mainly in circumventricular organs situated outside the blood-brain barrier, and LC-MS/MS measurement of MT-II in brain and plasma indicated negligible brain penetration [6]. A validated LC-MS/MS assay applied in mice after intraperitoneal administration likewise found rapid plasma clearance and only low brain-homogenate concentrations relative to plasma, which the authors interpreted as confirming low brain penetrability in that species [8]. Feeding and energy-balance endpoints dominate the animal literature. Seven-day central infusion of MT-II in male rats produced near-complete anorexia for one to two days followed by a return of feeding despite continued infusion, reduced fat pad weight relative to pair-fed controls, and largely cancelled neuropeptide Y-driven hyperphagia, increased adiposity, and rises in insulin and leptin, while failing to reverse NPY-driven suppression of the gonadotropic and somatotropic axes [4]. In rats, intracerebroventricular MT-II increased gastrin-releasing peptide mRNA expression in the hypothalamic paraventricular nucleus, an effect opposite in direction to that of 38-hour food deprivation [17]. Non-mammalian models have also been used: intracerebroventricular MT-II attenuated re-feeding in food-deprived ring doves [10], a single intravenous injection of MT-II attenuated food intake in both broiler and layer chick strains [19], and in goldfish the anorexigenic effect of intracerebroventricular MT-II was abolished by a CRH 1/2 receptor antagonist [20]. Metabolic and neuroendocrine studies have used MT-II as a pharmacological probe of MC3/4 receptor signalling. In streptozotocin-diabetic rats, leptin's glucose-lowering action was blocked by the MC3/4R antagonist SHU9119, whereas intracerebroventricular melanotan-II alone did not reproduce leptin's correction of the metabolic or neuroendocrine disturbances of uncontrolled diabetes [13]. In mice with arcuate proopiomelanocortin deficiency, central melanotan II administration reversed the observed alterations in glucose tolerance and glycosuria [15]. Electrophysiological and neuroanatomical work in MC4R-GFP reporter mice reported that leptin, but not melanotan II, hyperpolarised most lateral hypothalamic MC4R-GFP neurons [11]. In rat brainstem, microinjection of MT-II into the dorsal motor vagal nucleus decreased phasic gastric contractions in an effect blocked by SHU9119 or ipsilateral vagotomy, and bath-applied MT-II reduced spontaneous action potentials in labelled DMV antrum neurons but not in MC4R-null mice [16]. Behavioural pharmacology in animals spans several domains. In ovariectomised female rats primed with estradiol benzoate plus progesterone, intravenous MT-II increased hops, darts, and ear wiggling without altering pacing or lordosis, and no effect was observed with estradiol priming alone [5]. A study of erectile activity in rats ex copula reported that alpha-MSH and melanotan-II stimulate erectile activity across species and used a selective MC4 receptor agonist and antagonists to attribute melanocortin erectogenesis to MC4 receptors [14]. In prairie voles, peripherally administered MTII enhanced partner preference formation, an effect not seen in non-monogamous meadow voles and prevented by co-administration of an oxytocin receptor antagonist, with MTII also activating hypothalamic oxytocin neurons [9]. In ethanol-drinking studies, MTII reduced ethanol intake similarly in Mc3r-deficient and wild-type mice [12], and in a later report central MTII reduced ethanol drinking in Mc4r wild-type but not Mc4r knockout mice, whereas intraperitoneal MTII reduced drinking in both genotypes and also attenuated intake of sucrose and saccharin [18]. In a chronic unpredictable stress model in male Sprague-Dawley rats, daily intraperitoneal MT-II attenuated stress-induced anhedonia, body-weight-gain suppression, adrenal hypertrophy, and reductions in hippocampal BDNF, with no change detected in forced swim test immobility [1].